Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands
Texas
77381-1160
United States
Tel: 281-863-3000
Fax: 281-863-8088
Website: http://www.lexpharma.com/
415 articles about Lexicon Pharmaceuticals, Inc.
-
Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021
4/29/2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets close.
-
Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
4/8/2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 a.m. ET.
-
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical UpdateConference Call and Webcast at 5:00 pm Eastern Time
3/10/2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones.
-
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021
3/4/2021
Lexicon Pharmaceuticals, Inc., will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close.
-
Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
1/14/2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure,
-
Lexicon Pharmaceuticals to Participate in the 39th Annual J.P. Morgan Healthcare Conference
1/6/2021
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com . An archived version of the webcast will be available on the website for two week
-
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
12/31/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing in RELIEF-PHN 1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of post-herpetic neuralgia. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). “We are pleased to commence dosing in our second proof-of-concept study of LX9211,” said Praveen Tyle, Ph.D.
-
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
12/16/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon’s patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon. “In line with our realignment aroun
-
Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain
12/11/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.
-
Lexicon Announces Offering of Common Stock
12/11/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value $0.001 (the “Common Stock”), at a price of $3.20 per share, for aggregate gross proceeds to the Company of $65,000,000 before deducting fees to the placement agent a
-
Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine
11/17/2020
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
-
Lexicon Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
11/16/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following conference: Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 Lonnel Coats, Lexicon’s president and chief executive officer, and Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will participate in a live fireside chat on Wednesday, November 18
-
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical UpdateConference Call and Webcast at 8:00 am Eastern Time
10/29/2020
Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended September 30, 2020 and provided an update of key milestones.
-
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020
10/27/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a clinical update.
-
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
9/8/2020
Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.
-
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
9/4/2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). “We are pleased to progress with patient dosing in our first proof-of-
-
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference
9/3/2020
Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will make a live webcast company presentation for the Wells Fargo conference on Thursday, September 10, 2020 at 2:00 p.m. ET.
-
GTCR and TerSera Therapeutics Announce Acquisition of Xermelo
8/3/2020
GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.
-
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
7/30/2020
Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain
-
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update21% Increase in XERMELO® U.S. Net Sales
7/30/2020
Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended June 30, 2020.